Medpace Holdings (MEDP) Total Non-Current Liabilities (2015 - 2026)
Medpace Holdings' (MEDP) quarterly Total Non-Current Liabilities came in at $1.6 billion in Q2 2026, up 16.06% on a YoY basis from $1.3 billion in Q2 2025, and up 6.29% quarter-over-quarter from $1.5 billion in Q1 2026.
Analysis
Medpace Holdings (MEDP) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
Medpace Holdings (MEDP) has reported Total Non-Current Liabilities for 12 consecutive years, with $1.6 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Total Non-Current Liabilities rose 16.06% year-over-year to $1.6 billion; the trailing twelve-month figure through Jun 2026 stood at $1.6 billion (up 16.06% YoY), and the FY2025 full-year result was $1.5 billion, up 18.35% from the prior year.
- Total Non-Current Liabilities climbed to $1.6 billion in Q2 2026 per MEDP's latest filing, from $1.5 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.6 billion in Q2 2026 and bottomed at $722.1 million in Q1 2022.
- Historically, Total Non-Current Liabilities has averaged $1.2 billion across 5 years, with a median of $1.1 billion in 2024.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities soared 68.68% in 2022, then retreated 2.17% in 2023.
- Over 5 years, Total Non-Current Liabilities stood at $943.4 million in 2022, then gained by 13.38% to $1.1 billion in 2023, then advanced by 15.23% to $1.2 billion in 2024, then increased by 18.35% to $1.5 billion in 2025, then increased by 7.2% to $1.6 billion in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $1.6 billion, $1.5 billion, and $1.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | 22.94 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | 1.56 Bn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | 6.94 Bn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | 4.24 Bn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | 2.15 Bn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | 30.49 Mn |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | 553.39 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | 28.62 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | - |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.56 Bn |
| Mar 31, 2026 | 1.47 Bn |
| Dec 31, 2025 | 1.46 Bn |
| Sep 30, 2025 | 1.40 Bn |
| Jun 30, 2025 | 1.35 Bn |
| Mar 31, 2025 | 1.25 Bn |
| Dec 31, 2024 | 1.23 Bn |
| Sep 30, 2024 | 1.17 Bn |
| Jun 30, 2024 | 1.13 Bn |
| Mar 31, 2024 | 1.10 Bn |
| Dec 31, 2023 | 1.07 Bn |
| Sep 30, 2023 | 992.69 Mn |
| Jun 30, 2023 | 992.93 Mn |
| Mar 31, 2023 | 1.03 Bn |
| Dec 31, 2022 | 943.41 Mn |
| Sep 30, 2022 | 960.98 Mn |
| Jun 30, 2022 | 1.01 Bn |
| Mar 31, 2022 | 722.11 Mn |
| Dec 31, 2021 | 689.26 Mn |
| Sep 30, 2021 | 663.00 Mn |